Press Releases

PASADENA, Calif. --(BUSINESS WIRE)--Jun. 18, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted

PASADENA, Calif. --(BUSINESS WIRE)--Jun. 2, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global Healthcare Conference – June 2-4, 2026 Type: Fireside Chat Presentation Date/Time: June 3,

- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic dysfunction - ARO-INHBE produced meaningful reductions in liver fat content as a monotherapy or in combination with low-dose tirzepatide in

- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the

- Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data published in The New England Journal of Medicine demonstrated a 46% reduction in liver fat in homozygous patients and a well-tolerated safety

PASADENA, Calif. --(BUSINESS WIRE)--May 4, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference – May 12-14, 2026 Type: Investor Group Dinner Date/Time: May 12, 2026

– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of

– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 20, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026.